The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels. However, after rituximab some patients develop hypogammaglobulinaemia. We performed a single centre retrospe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC musculoskeletal disorders 2014-05, Vol.15 (1), p.178-178, Article 178
Hauptverfasser:	Marco, Helena, Smith, Rona M, Jones, Rachel B, Guerry, Mary-Jane, Catapano, Fausta, Burns, Stella, Chaudhry, Afzal N, Smith, Kenneth G C, Jayne, David R W
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Agammaglobulinemia - blood Agammaglobulinemia - chemically induced Agammaglobulinemia - diagnosis Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived - adverse effects Antibodies, Monoclonal, Murine-Derived - therapeutic use Autoimmune diseases Autoimmune Diseases - blood Autoimmune Diseases - diagnosis Autoimmune Diseases - drug therapy Care and treatment Complications and side effects Drug therapy Female Follow-Up Studies Humans Immune system Immunoglobulins - blood Immunologic Factors - adverse effects Immunologic Factors - therapeutic use Lupus Lymphoma Male Measurement Middle Aged Retrospective Studies Rituximab Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!